Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 01/20 10:01:02 pm
62.53 USD   +3.65%
01/20 MERCK : Announces Settlement and License Agreement Resolving KEYTRUD..
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/20 DOW MOVERS : Ge, mrk
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/21/2012 | 11:46am CET

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

MAIN FACTS:

-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at tapan.panchal@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
01/20 MERCK : Announces Settlement and License Agreement Resolving KEYTRUDA® (pembroli..
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/20 DOW MOVERS : Ge, mrk
01/19 STUDIES FROM MERCK & COMPANY PROVIDE : PCSK9 as an...
01/19 MERCK : Reports Outline Pharmacology and Toxicology Study Findings from Merck & ..
01/19 MERCK : Researchers at Merck & Company Discuss Findings in Bioanalysis (Reductio..
01/19 INCYTE : and Merck to Advance Clinical Development Program Investigating the Com..
01/19 MERCK : Recent Findings from Merck & Company Advance Knowledge in Bioanalysis (A..
01/19 MERCK : to Participate at the 35th Annual J.P. Morgan Healthcare Conference
01/19 RESEARCHERS AT MERCK & COMPANY TARGE : A Powerful...
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/20 SNIPPET ROUNDUP : Opdivo's First-Line Lung Combo Delay And Colucid's Lilly Windf..
01/20 ASCO-GI : Opdivo Heads Close Pack Of Anti-PD-1s In Gastric Cancer
01/20 Merck settles Keytruda patent fight with Bristol-Myers and Ono Pharma, agrees..
01/20 Implications Of The Latest Smash In Bristol-Myers Squibb Stock
01/20 Why Gilead Is Undervalued
Advertisement
Financials ($)
Sales 2016 39 931 M
EBIT 2016 13 699 M
Net income 2016 5 950 M
Debt 2016 3 981 M
Yield 2016 2,97%
P/E ratio 2016 30,17
P/E ratio 2017 17,86
EV / Sales 2016 4,42x
EV / Sales 2017 4,37x
Capitalization 172 404 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,2 $
Spread / Average Target 9,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.6.22%172 404
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
SANOFI-1.66%104 532
More Results